奥泰生物
(688606)
| 流通市值：34.59亿 | | | 总市值：34.59亿 |
| 流通股本：7565.44万 | | | 总股本：7565.44万 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 392,144,917.68 | 195,372,450.28 | 905,344,393.81 | 633,076,568.3 |
| 营业总成本 | 345,033,080.78 | 178,180,947.39 | 711,573,116.92 | 457,636,927.5 |
| 其他经营收益 | | | | |
| 营业利润 | 53,990,232.16 | 21,643,668.11 | 251,810,099.85 | 218,808,577.65 |
| 利润总额 | 54,022,896.75 | 21,759,923.13 | 251,176,669.04 | 218,245,963.24 |
| 净利润 | 50,642,133.11 | 19,130,988.4 | 220,071,907.4 | 189,723,134.17 |
| 每股收益 | | | | |
| 其他综合收益 | 361,784.48 | 308,042.58 | -361,475.92 | -608,935.67 |
| 综合收益总额 | 51,003,917.59 | 19,439,030.98 | 219,710,431.48 | 189,114,198.5 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,567,677,911.51 | 2,692,006,061.63 | 2,831,759,538.42 | 2,927,645,354.46 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,429,685,958.93 | 1,417,050,296.61 | 1,410,665,422.25 | 1,314,380,983.96 |
| 资产总计 | 3,997,363,870.44 | 4,109,056,358.24 | 4,242,424,960.67 | 4,242,026,338.42 |
| 流动负债: | | | | |
| 流动负债合计 | 229,342,973.54 | 217,834,785.06 | 286,644,560.7 | 329,541,409.28 |
| 非流动负债: | | | | |
| 非流动负债合计 | 7,873,059.02 | 8,956,870.96 | 9,441,456.35 | 11,137,443.03 |
| 负债合计 | 237,216,032.56 | 226,791,656.02 | 296,086,017.05 | 340,678,852.31 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,760,727,808.92 | 3,882,888,640.38 | 3,946,690,966.34 | 3,901,773,832.63 |
| 股东权益合计 | 3,760,147,837.88 | 3,882,264,702.22 | 3,946,338,943.62 | 3,901,347,486.11 |
| 负债和股东权益合计 | 3,997,363,870.44 | 4,109,056,358.24 | 4,242,424,960.67 | 4,242,026,338.42 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 465,249,438.74 | 203,591,692.47 | 969,568,433.87 | 671,775,561.77 |
| 经营活动现金流出小计 | 412,364,429.74 | 235,773,519.52 | 762,975,443.49 | 557,315,959.78 |
| 经营活动产生的现金流量净额 | 52,885,009 | -32,181,827.05 | 206,592,990.38 | 114,459,601.99 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,200,106,370.01 | 987,653,036.97 | 2,101,166,416.22 | 1,661,986,279.02 |
| 投资活动现金流出小计 | 203,018,964.99 | 174,049,615.71 | 1,955,492,072.06 | 1,582,074,613.04 |
| 投资活动产生的现金流量净额 | 997,087,405.02 | 813,603,421.26 | 145,674,344.16 | 79,911,665.98 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 286,068.78 | 286,068.78 | 20,003,703.77 | 10,357,453.01 |
| 筹资活动现金流出小计 | 243,132,397.64 | 86,152,015.46 | 198,008,723.05 | 118,677,423.8 |
| 筹资活动产生的现金流量净额 | -242,846,328.86 | -85,865,946.68 | -178,005,019.28 | -108,319,970.79 |
| 汇率变动对现金及现金等价物的影响 | -29,135,405.72 | -14,518,117.23 | -11,836,543.94 | -5,492,523.53 |
| 现金及现金等价物净增加额 | 777,990,679.44 | 681,037,530.3 | 162,425,771.32 | 80,558,773.65 |
| 期末现金及现金等价物余额 | 1,840,753,406.35 | 1,748,017,537.21 | 1,062,762,726.91 | 980,895,729.24 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 777,990,679.44 | - | 162,425,771.32 | - |